Watson Didn’t Infringe Mucinex Patent: Fed. Circ.
The appeals court found that the district court correctly construed the claims of U.S. Patent Number 6,372,252, and determined that because Watson’s generic version had a different formulation than the branded drug, it did not violate the patent.
Reckitt sued Watson in the Southern District of Florida in April 2009, claiming the defendant's abbreviated new drug application to market guaifenesin tablet formulations...
To view the full article, register now.